Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections

Savino, Gustavo; Battendieri, Remo; Gari, Mariangela; Caputo, Carmela Grazia; Laurenti, Luca; Blasi, Maria Antonietta

doi:10.1007/s00432-013-1438-9

Cited by 44 publications

(13 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Intralesional rituximab therapy has been used in the treatment of primary B-cell cutaneous lymphoma with equivalent response rates, fewer adverse effects, and lower cost as compared to systemic rituximab treatment [107]. Recent case reports have commented on the efficacy of using intralesional injections in the treatment of relapsed and recurrent OALs [80, 81, 108, 109]. Intralesional rituximab is delivered as four weekly injections of approximately 1.5 mL followed by six monthly injections of the same, with the aid of topical anesthesia.…”

Section: Reviewmentioning

confidence: 99%

Classification, diagnosis, and management of conjunctival lymphoma

2019

View full text Add to dashboard Cite

Lymphoma is a malignant lymphoproliferative tumor that can involve the conjunctiva. Approximately 5–15% of all extranodal lymphomas are found in the ocular adnexal region, with approximately 25% of those involving the conjunctiva. Ninety-eight percent of conjunctival lymphomas arise from B-lymphocytes. The most common subtype of conjunctival lymphoma is extranodal marginal zone lymphoma (80%), followed by follicular lymphoma (8%), diffuse large B-cell lymphoma (3%) and mantle cell lymphoma (3%). Natural killer and T cells (NK/T) are rare causes of lymphoma. While most conjunctival lymphomas are localized to the ocular adnexa at the time of presentation, systemic examination and management are of key importance in the long-term care of the patient. This review outlines the classification, etiology, presentation, diagnosis, and management of conjunctival lymphoma. The novel use of high resolution optical coherence tomography, both as a diagnostic tool and as a means for ongoing evaluation during treatment, is illustrated. Treatment options discussed include external beam radiation, chemotherapy, immunotherapy, antibiotic therapy, and combination regimens. Future investigation of the etiology and pathogenesis of conjunctival lymphoma is expected to reveal opportunities for innovative and individualized therapeutic agents. Collaboration between multiple disciplines is key in the advancement of the field.

show abstract

Section: Reviewmentioning

confidence: 99%

Classification, diagnosis, and management of conjunctival lymphoma

2019

View full text Add to dashboard Cite

show abstract

“…20 At 48-month long-term follow-up, intralesional administration of rituximab for treating localized CD20 þ OAL was considered to be an effective front-line therapeutic option with negligible adverse effects and with good response rate and duration. 21 Tuncer et al 22 evaluated the effect of systemic rituximab monotherapy (375 mg/m 2 provided intravenously once every 3 weeks for 6 to 8 cycles) with 11 eyes in 10 patients with OAL. Complete regression of primary OAL without recurrence was observed in about one-third of eyes after systemic rituximab monotherapy.…”

Section: Discussionmentioning

confidence: 99%

Ocular Adnexal Lymphomas: Single-Center Experience

Özkan

Palamar

Tombuloğlu

et al. 2015

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

“…More recently, intralesional anti-CD20 rituximab has been evaluated for efficacy in clinical trials with promising results. The present patient received local radiotherapy and remains tumor-free 11 months after treatment [21]. …”

Section: Discussionmentioning

confidence: 99%

Clinicopathologic and Magnetic Resonance Imaging Analysis of a Multifocal Orbital Lymphoid Tumor

et al. 2017

View full text Add to dashboard Cite

Objective: To distinguish between a multifocal orbital lymphoid tumor and a major simulator represented by a diffuse lymphaticovenous malformation. Methods: We performed a comparison of clinical and radiographic (magnetic resonance imaging [MRI]) findings of these two disparate entities and demonstrated how a misdiagnosis can be prevented. Results: Orbital lymphoid tumors develop in adults at around 60 years of age, whereas extensive lymphaticovenous malformations are generally detected in the first decade. Despite these differences, this is the first description of clinical confusion between them. MRI with gadolinium injection in the current lymphoid tumor displayed a low signal on T2-weighted images, rapid and uniform enhancement, and reduced diffusion. Lymphaticovenous malformations are heterogeneous, display poor or only focal perfusion, and fail to exhibit diminished diffusion. Newer techniques such as diffusion-weighted imaging and dynamic contrast-enhanced imaging may be able to provide additional differential diagnostic information. The final pathologic diagnosis was an extranodal marginal zone lymphoma. Conclusions: Despite the obvious distinctions between orbital lymphoid tumors and lymphaticovenous malformations, several clinical radiologic specialists misdiagnosed the present orbital lesion as a vascular lesion. A combined clinicoradiographic analysis should obviate such errors and facilitate the correct diagnosis in the future.

show abstract

Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections

Abstract: This study suggests that intralesional administration of rituximab for treating localized ocular adnexal CD20+ lymphomas could be an effective front-line therapeutic option with negligible side effects and a good response rate and duration.

Cited by 44 publications

References 19 publications

Classification, diagnosis, and management of conjunctival lymphoma

Classification, diagnosis, and management of conjunctival lymphoma

Ocular Adnexal Lymphomas: Single-Center Experience

Clinicopathologic and Magnetic Resonance Imaging Analysis of a Multifocal Orbital Lymphoid Tumor

Contact Info

Product

Resources

About